Medical and Pharmaceutical bioAffinity Technologies soars Monday as non-invasive lung cancer tech gains traction Shares rose by 73% during the session with no immediate catalyst Rowan DunneMarch 23, 2026
Medical and Pharmaceutical bioAffinity launches 2,000-patient study for noninvasive lung cancer test The test analyzes sputum samples using flow cytometry to identify cancer-related cellular changes Joseph MortonMarch 11, 2026
Medical and Pharmaceutical bioAffinity Technologies shines After CyPath Lung Clinical case studies CyPath Lung showed remarkable accuracy in identifying lung cancer at its earliest stage Joseph MortonSeptember 29, 2025
Medical and Pharmaceutical bioAffinity Technologies obtains Canadian patent for lung cancer spit test The CyPath Lung screening tool is also patented in China, Australia and Japan Rowan DunneJuly 22, 2025
Medical and Pharmaceutical bioAffinity Technologies secures Australian patent for ‘CyPath Lung’ spit test It will be issued within 3 months provided that there are no opposition filings made by third parties Rowan DunneJanuary 22, 2025